Internal Medicine is a distinguished peer-reviewed journal published by the Japan Society of Internal Medicine, focusing on the nuanced field of internal medicine. Since its inception in 1974 and with a commitment to advancing medical knowledge, the journal has evolved remarkably, aiming to disseminate high-quality research that contributes to the understanding and treatment of internal diseases. Operating from Tokyo, Japan, it provides an intellectual platform for researchers and clinicians to publish original articles, reviews, and case studies that address various aspects of internal medicine. The journal currently holds a ranking in the Q3 quartile for both Internal Medicine and miscellaneous Medicine categories as of 2023, signifying its growing influence in the medical community. Although not an open-access journal, it remains accessible to a wide audience through institutional subscriptions, enhancing its reach among professionals and students alike. With its commitment to excellence, Internal Medicine serves as an essential resource for those seeking the latest developments and research within this vital medical field.

Rare Tumors, published by SAGE Publications Ltd, is a premier open-access journal dedicated to advancing the understanding and research of rare neoplasms. With the ISSN 2036-3605 and E-ISSN 2036-3613, this journal provides a vital platform for sharing innovative research findings and clinical insights since its inception in 2009. Situated in Italy, Rare Tumors has a converged publication timeline from 2010 to 2024 and aims to foster a supportive community for researchers and professionals in the oncology and histology fields. It has achieved a notable Q3 ranking in Oncology and Q4 in Histology as of 2023, reflecting its crucial role in bridging the knowledge gap in these specialized areas. Despite its relatively humble Scopus ranks, the journal's open-access model ensures that vital information reaches a broad audience, including those in academia, clinical practice, and beyond. It aspires to not only document rare tumor cases but also stimulate dialogue on their diagnosis, treatment, and management strategies, making it an indispensable resource for anyone dedicated to tackling the challenges posed by rare tumors.

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

Medical Mycology Case Reports, published by Elsevier, is a pivotal journal dedicated to advancing the field of mycology through the presentation of case reports that highlight clinical findings, diagnostic challenges, and treatment outcomes associated with fungal infections. With its ISSN 2211-7539 and E-ISSN 2211-7539, this open-access journal has been serving the global community since 2012, allowing unrestricted access to its valuable insights. Situated in the Netherlands, specifically at RADARWEG 29, AMSTERDAM, this journal has gained recognition in areas such as Infectious Diseases (ranked Q3) and Microbiology (ranked Q4) as of 2023. Its commitment to disseminating high-quality research is reflected in its Scopus rankings, which place it at the 51st percentile in Medicine and the 32nd percentile in Immunology and Microbiology. By bridging the gap between clinical cases and academic research, Medical Mycology Case Reports plays a crucial role in enriching the knowledge base of practitioners and researchers alike, ultimately contributing to improved patient management and public health.

BMJ Case Reports is a vital resource within the field of medicine, published by the esteemed BMJ PUBLISHING GROUP. With an E-ISSN of 1757-790X and a focus on disseminating high-quality case reports, this journal serves as a platform for healthcare professionals, researchers, and students to share unique clinical experiences and uncommon presentations of medical conditions. Since its inception in 2008 and continuing through 2024, it has gained recognition for contributing to the advancement of medical knowledge, currently ranking at Q4 in the Medicine (miscellaneous) category and positioned in the 54th percentile in General Medicine according to Scopus rankings. Although it is a subscription-based journal, its impact on clinical practice and education is significant, enabling practitioners to learn from diverse case studies and improving patient care outcomes. As it aims to enhance the understanding of rare and significant medical cases, BMJ Case Reports remains an essential publication for those at the forefront of medical innovation.

Thoracic and Cardiovascular Surgeon Reports is a pivotal academic journal dedicated to the dissemination of innovative research and clinical practices in the fields of thoracic and cardiovascular surgery. Published by GEORG THIEME VERLAG KG, this journal has been an open-access publication since 2013, fostering a broader reach and enhancing visibility for authors and researchers globally. With its commitment to high-quality peer-reviewed articles, Thoracic and Cardiovascular Surgeon Reports serves as an essential platform for surgeons, clinicians, and scholars to share findings that advance medical knowledge, improve patient outcomes, and refine surgical techniques. The journal aims to bridge the gap between research and practical application, catering to an audience keen on staying updated with the latest in thoracic and cardiovascular interventions, making it a valuable resource in an ever-evolving medical landscape.

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

The Journal of Kidney Cancer and VHL stands as a leading platform for disseminating cutting-edge research in the field of renal oncology, particularly focused on kidney cancer and Von Hippel-Lindau (VHL) disease. Published by CODON PUBLICATIONS since its inception, this Open Access journal, with ready accessibility since 2014, aims to foster knowledge exchange and collaboration among researchers, clinicians, and healthcare professionals dedicated to improving outcomes for patients with kidney cancer. With an ISSN of 2203-5826, this journal serves as a vital resource in the academic community, encouraging submissions that span various topics, including epidemiology, treatment modalities, and innovative therapeutic strategies. By providing unrestricted access to its content, the Journal of Kidney Cancer and VHL promotes inclusive participation in the global dialogue surrounding these critical health challenges, ensuring that the latest findings reach all corners of the scientific community.